EL
Insider
Evan Lippman
EVP, Business DevelopmentEvan Lippman (EVP, Business Development) filed 2 Form 4 reports in the trailing twelve months (0 purchases, 2 sales), most often in Teva Pharmaceutical Industries Limited (TEVA). The largest single filing was $1.5M of TEVA (41,658 sh across 2 lots, as filed), executed May 14.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
2
0 buys · 2 sells
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$2.2M
shares × price, as filed
Last traded
Aug 17
Filed Aug 19
Median ADV $196.1M across their filed names
Open performance→Volume by month
Buys $0
Sells $2.2M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
TEVARecent filings
TEVASALE
Teva Pharmaceutical Industries Limited
View filing →
$680K18,600 sh × $36.57
Exec Aug 17
Filed Aug 19 · 4:00 PM ET TEVASALE Teva Pharmaceutical Industries Limited View filing → $1.5M
41,658 sh across 2 lots
Exec May 14
Filed May 18 · 5:30 PM ET